{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T09:20:45Z","timestamp":1780564845118,"version":"3.54.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"6-7","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,20]],"date-time":"2013-07-20T00:00:00Z","timestamp":1374278400000},"content-version":"vor","delay-in-days":1510,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004431","name":"Fondation de France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004431","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1016\/j.acvd.2009.03.012","type":"journal-article","created":{"date-parts":[[2009,6,12]],"date-time":"2009-06-12T10:07:11Z","timestamp":1244801231000},"page":"485-496","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial"],"prefix":"10.1016","volume":"102","author":[{"given":"Jean-Philippe","family":"Collet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Montalescot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe Gabriel","family":"Steg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Steinhubl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A.A.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting Fei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Claiborne","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian W.","family":"Hamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Topol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.acvd.2009.03.012_bib1","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of clopidogrel to aspirin in 45,852\u00a0patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2009.03.012_bib2","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/eurheartj\/ehi138","article-title":"Guidelines for percutaneous coronary interventions. The task force for percutaneous coronary interventions of the European Society of Cardiology","volume":"26","author":"Silber","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2009.03.012_bib3","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2009.03.012_bib4","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2009.03.012_bib5","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1161\/01.CIR.0000015464.18023.0A","article-title":"Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin\u00a0I, C-reactive protein, and B-type natriuretic peptide","volume":"105","author":"Sabatine","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2009.03.012_bib6","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1093\/eurheartj\/ehl334","article-title":"A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279\u00a0patients at risk for coronary artery disease","volume":"27","author":"Biondi-Zoccai","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2009.03.012_bib7","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1161\/01.CIR.0000145171.89690.B4","article-title":"Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes","volume":"110","author":"Collet","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2009.03.012_bib8","doi-asserted-by":"crossref","unstructured":"Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2006 [published online: Dec 5, 2006: doi:10.1001\/jama.297.2.joc60179].","DOI":"10.1001\/jama.297.16.1770-c"},{"key":"10.1016\/j.acvd.2009.03.012_bib9","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S0735-1097(00)00521-0","article-title":"Catastrophic outcomes of noncardiac surgery soon after coronary stenting","volume":"35","author":"Kaluza","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2009.03.012_bib10","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1016\/j.jacc.2006.10.026","article-title":"Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents","volume":"48","author":"Pfisterer","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2009.03.012_bib11","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1093\/bja\/ael083","article-title":"Coronary artery stenting and non-cardiac surgery \u2013 a prospective outcome study","volume":"96","author":"Vicenzi","year":"2006","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.acvd.2009.03.012_bib12","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.amjmed.2006.01.023","article-title":"Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials","volume":"119","author":"Bavry","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.acvd.2009.03.012_bib13","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/hrt.2005.061622","article-title":"Drug eluting stents: an updated meta-analysis of randomised controlled trials","volume":"92","author":"Roiron","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.acvd.2009.03.012_bib14","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.106.174516","article-title":"AHA\/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute","volume":"113","author":"Smith","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2009.03.012_bib15","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1161\/CIRCULATIONAHA.106.618066","article-title":"Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry","volume":"113","author":"Spertus","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2009.03.012_bib16","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2009.03.012_bib17","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S0002-9149(02)02272-5","article-title":"Patient-reported frequency of taking aspirin in a population with coronary artery disease","volume":"89","author":"Allen LaPointe","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.acvd.2009.03.012_bib18","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(05)67760-4","article-title":"Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial","volume":"366","author":"Granger","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2009.03.012_bib19","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1001\/archinte.166.17.1842","article-title":"Impact of medication therapy discontinuation on mortality after myocardial infarction","volume":"166","author":"Ho","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.acvd.2009.03.012_bib20","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1161\/01.CIR.0000051362.96946.15","article-title":"Early and late effects of clopidogrel in patients with acute coronary syndromes","volume":"107","author":"Yusuf","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2009.03.012_bib21","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1001\/jama.299.5.532","article-title":"Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome","volume":"299","author":"Ho","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2009.03.012_bib22","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.thromres.2006.01.019","article-title":"Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the verify thrombosis risk assessment (VERITAS) study","volume":"119","author":"Malinin","year":"2007","journal-title":"Thromb Res"},{"issue":"Suppl. G","key":"10.1016\/j.acvd.2009.03.012_bib23","doi-asserted-by":"crossref","first-page":"G46","DOI":"10.1093\/eurheartj\/sul055","article-title":"Premature withdrawal and alternative therapies to dual oral antiplatelet therapy","volume":"8","author":"Collet","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2009.03.012_bib24","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jacc.2006.10.004","article-title":"Noncardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events","volume":"49","author":"Schouten","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2009.03.012_bib25","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1056\/NEJMoa067484","article-title":"Analysis of 14\u00a0trials comparing sirolimus-eluting stents with bare-metal stents","volume":"356","author":"Kastrati","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2009.03.012_bib26","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1056\/NEJMoa067731","article-title":"Stent thrombosis in randomized clinical trials of drug-eluting stents","volume":"356","author":"Mauri","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2009.03.012_bib27","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa066633","article-title":"A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents","volume":"356","author":"Spaulding","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2009.03.012_bib28","doi-asserted-by":"crossref","unstructured":"CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329\u201339.","DOI":"10.1016\/S0140-6736(96)09457-3"},{"key":"10.1016\/j.acvd.2009.03.012_bib29","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2007.03.025","article-title":"Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial","volume":"49","author":"Bhatt","year":"2007","journal-title":"J Am Coll Cardiol"}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213609001478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213609001478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:36:50Z","timestamp":1761745010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875213609001478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":29,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S1875213609001478"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2009.03.012","relation":{},"ISSN":["1875-2136"],"issn-type":[{"value":"1875-2136","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2009.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}